Zhou W, Jiang L, Liao S, et al., 2023, Vaccines’ New Era-RNA Vaccine. Viruses, 15(8): 1760.

Sahin U, Kariko K, Tureci O, 2014, mRNA-Based Therapeutics—Developing a New Class of Drugs. Nat Rev Drug Discov, 13(10): 759–780.

Teo SP, 2022, Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. J Pharm Pract, 35(6): 947–951.

Fang E, Liu X, Li M, et al., 2022, Advances in COVID-19 mRNA Vaccine Development. Signal Transduct Target Ther, 7(1): 94.

Corbett KS, Edwards DK, Leist SR, et al., 2020, SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness. Nature, 586(7830): 567–571.

Sahin U, Muik A, Derhovanessian E, et al., 2020, COVID-19 Vaccine BNT162b1 Elicits Human Antibody and TH1 T Cell Responses. Nature, 586(7830): 594–599.

Kozak M, 1987, At Least Six Nucleotides Preceding the AUG Initiator Codon Enhance Translation in Mammalian Cells. J Mol Biol, 196(4): 947–950.

Mayr C, 2019, What Are 3’ UTRs Doing? Cold Spring Harb Perspect Biol, 11(10): a034728.

Wadhwa A, Aljabbari A, Lokras A, et al., 2020, Opportunities and Challenges in the Delivery of mRNA-Based Vaccines. Pharmaceutics, 12(2): 102.

Kariko K, Muramatsu H, Keller JM, et al., 2012, Increased Erythropoiesis in Mice Injected with Submicrogram Quantities of Pseudouridine-Containing mRNA Encoding Erythropoietin. Mol Ther, 20(5): 948–953.

Gustafsson C, Govindarajan S, Minshull J, 2004, Codon Bias and Heterologous Protein Expression. Trends Biotechnol, 22(7): 346–353.

Grier AE, Burleigh S, Sahni J, et al., 2016, pEVL: A Linear Plasmid for Generating mRNA IVT Templates with Extended Encoded Poly(A) Sequences. Mol Ther Nucleic Acids, 5(4): e306.

Lima SA, Chipman LB, Nicholson AL, et al., 2017, Short poly(A) Tails Are a Conserved Feature of Highly Expressed Genes. Nat Struct Mol Biol, 24(12): 1057–1063.

Xia X, 2021, Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel), 9(7): 734.

Mckay PF, Hu K, Blakney AK, et al., 2020, Self-Amplifying RNA SARS-CoV-2 Lipid Nanoparticle Vaccine Candidate Induces High Neutralizing Antibody Titers in Mice. Nat Commun, 11(1): 3523.

Fuller DH, Berglund P, 2020, Amplifying RNA Vaccine Development. N Engl J Med, 382(25): 2469–2471.

Beissert T, Perkovic M, Vogel A, et al., 2020, A Trans-Amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity. Mol Ther, 28(1): 119–128.

Kristensen LS, Andersen MS, Stagsted LVW, et al., 2019, The Biogenesis, Biology and Characterization of Circular RNAs. Nat Rev Genet, 20(11): 675–691.

Chen R, Wang SK, Belk JA, et al., 2023, Engineering Circular RNA for Enhanced Protein Production. Nat Biotechnol, 41(2): 262–272.

Phua KKL, Leong KW, Nair SK, 2013, Transfection Efficiency and Transgene Expression Kinetics of mRNA Delivered in Naked and Nanoparticle Format. J Control Release, 166(3): 227–233.

Van Lint S, Goyvaerts C, Maenhout S, et al., 2012, Preclinical Evaluation of TriMix and Antigen mRNA-Based Antitumor Therapy. Cancer Res, 72(7): 1661–1671.

Abbasi S, Matsui-Masai M, Yasui F, et al., 2024, Carrier-Free mRNA Vaccine Induces Robust Immunity Against SARS-CoV-2 in Mice and Non-Human Primates Without Systemic Reactogenicity. Mol Ther, 32(5): 1266–1283.

Neumann E, Schaefer-Ridder M, Wang Y, et al., 1982, Gene Transfer into Mouse Lyoma Cells by Electroporation in High Electric Fields. EMBO J, 1(7): 841–845.

Aarntzen EHJG, Schreibelt G, Bol K, et al., 2012, Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients. Clin Cancer Res, 18(19): 5460–5470.

Sun X, Zeng L, Huang Y, 2019, Transcutaneous Delivery of DNA/mRNA for Cancer Therapeutic Vaccination. J Gene Med, 21(7): e3089.

Pardi N, Hogan MJ, Porter FW, et al., 2018, mRNA Vaccines—A New Era in Vaccinology. Nat Rev Drug Discov, 17(4): 261–279.

Qiu P, Ziegelhoffer P, Sun J, et al., 1996, Gene Gun Delivery of mRNA In Situ Results in Efficient Transgene Expression and Genetic Immunization. Gene Ther, 3(3): 262–268.

Peking P, Koller U, Hainzl S, et al., 2016, A Gene Gun-Mediated Nonviral RNA Trans-Splicing Strategy for Col7a1 Repair. Mol Ther Nucleic Acids, 5: e287.

Samulski RJ, Muzyczka N, 2014, AAV-Mediated Gene Therapy for Research and Therapeutic Purposes. Annu Rev Virol, 1(1): 427–451.

Kay MA, Glorioso JC, Naldini L, 2001, Viral Vectors for Gene Therapy: The Art of Turning Infectious Agents into Vehicles of Therapeutics. Nat Med, 7(1): 33–40.

Lundstrom K, 2016, Replicon RNA Viral Vectors as Vaccines. Vaccines (Basel), 4(4).

Beck JD, Reidenbach D, Salomon N, et al., 2021, mRNA Therapeutics in Cancer Immunotherapy. Mol Cancer, 20(1): 69.

Gu Y-Z, Zhao X, Song X-R, 2020, Ex Vivo Pulsed Dendritic Cell Vaccination Against Cancer. Acta Pharmacol Sin, 41(7): 959–969.

Pardi N, Tuyishime S, Muramatsu H, et al., 2015, Expression Kinetics of Nucleoside-Modified mRNA Delivered in Lipid Nanoparticles to Mice by Various Routes. J Control Release, 217: 345–351.

Cui S, Wang Y, Gong Y, et al., 2018, Correlation of the Cytotoxic Effects of Cationic Lipids with Their Headgroups. Toxicol Res (Camb), 7(3): 473–479.

Patel P, Ibrahim NM, Cheng K, 2021, The Importance of Apparent pKa in the Development of Nanoparticles Encapsulating siRNA and mRNA. Trends Pharmacol Sci, 42(6): 448–460.

Schlosser K, Taha M, Deng Y, et al., 2018, Systemic Delivery of MicroRNA Mimics with Polyethylenimine Elevates Pulmonary MicroRNA Levels, but Lacks Pulmonary Selectivity. Pulm Circ, 8(1): 2045893217750613.

Ulkoski D, Bak A, Wilson JT, et al., 2019, Recent Advances in Polymeric Materials for the Delivery of RNA Therapeutics. Expert Opin Drug Deliv, 16(11): 1149–1167.

Ke X, Shelton L, Hu Y, et al., 2020, Surface-Functionalized PEGylated Nanoparticles Deliver Messenger RNA to Pulmonary Immune Cells. ACS Appl Mater Interfaces, 12(32): 35835–35844.

Ding X, Wang A, Tong W, et al., 2019, Biodegradable Antibacterial Polymeric Nanosystems: A New Hope to Cope with Multidrug-Resistant Bacteria. Small, 15(20): e1900999.

Jarzebska N T, Mellett M, Frei J, et al., 2021, Protamine-Based Strategies for RNA Transfection. Pharmaceutics, 13(6): 877.

Papachristofilou A, Hipp MM, Klinkhardt U, et al., 2019, Phase Ib Evaluation of a Self-Adjuvanted Protamine Formulated mRNA-Based Active Cancer Immunotherapy, BI1361849 (CV9202), Combined with Local Radiation Treatment in Patients with Stage IV Non-Small Cell Lung Cancer. J Immunother Cancer, 7(1): 38.

Alberer M, Gnad-Vogt U, Hong HS, et al., 2017, Safety and Immunogenicity of a mRNA Rabies Vaccine in Healthy Adults: An Open-Label, Non-Randomized, Prospective, First-in-Human Phase 1 Clinical Trial. Lancet, 390(10101): 1511–1520.

Pardi N, Hogan MJ, Weissman D, 2020, Recent Advances in mRNA Vaccine Technology. Curr Opin Immunol, 65: 14–20.

Van Den Brand D, Gorris MAJ, Van Asbeck AH, et al., 2019, Peptide-Mediated Delivery of Therapeutic mRNA in Ovarian Cancer. Eur J Pharm Biopharm, 141: 180–190.

Hasannejad-Asl B, Pooresmaeil F, Takamoli S, et al., 2022, Cell Penetrating Peptide: A Potent Delivery System in Vaccine Development. Front Pharmacol, 13: 1072685.

Ho W, Gao M, Li F, et al., 2021, Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery. Adv Healthc Mater, 10(8): e2001812.

Cullis PR, Hope MJ, 2017, Lipid Nanoparticle Systems for Enabling Gene Therapies. Mol Ther, 25(7): 1467–1475.

Awasthi S, Hook LM, Pardi N, et al., 2019, Nucleoside-Modified mRNA Encoding HSV-2 Glycoproteins C, D, and E Prevents Clinical and Subclinical Genital Herpes. Sci Immunol, 4(39): eaaw7083.

Pardi N, Hogan MJ, Pelc RS, et al., 2017, Zika Virus Protection by a Single Low-Dose Nucleoside-Modified mRNA Vaccination. Nature, 543(7644): 248–251.

Li F, Zhang X Q, Ho W, et al., 2023, mRNA Lipid Nanoparticle-Mediated Pyroptosis Sensitizes Immunologically Cold Tumors to Checkpoint Immunotherapy. Nat Commun, 14(1): 4223.

Li W, Huang M, Wu Z, et al., 2024, mRNA-Lipid Nanoparticle-Mediated Restoration of PTPN14 Exhibits Antitumor Effects by Overcoming Anoikis Resistance in Triple-Negative Breast Cancer. Adv Sci (Weinh), 11(32): e2309988.

Eygeris Y, Gupta M, Kim J, et al., 2022, Chemistry of Lipid Nanoparticles for RNA Delivery. Acc Chem Res, 55(1): 2–12.

Sebastiani F, Yanez Arteta M, Lerche M, et al., 2021, Apolipoprotein E Binding Drives Structural and Compositional Rearrangement of mRNA-Containing Lipid Nanoparticles. ACS Nano, 15(4): 6709–6722.

Cheng Q, Wei T, Farbiak L, et al., 2020, Selective Organ Targeting (SORT) Nanoparticles for Tissue-Specific mRNA Delivery and CRISPR-Cas Gene Editing Nat Nanotechnol, 15(4): 313–320.

Kowalski PS, Rudra A, Miao L, et al., 2019, Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. Mol Ther, 27(4): 710–728.

Pollard C, Rejman J, De Haes W, et al., 2013, Type I IFN Counteracts the Induction of Antigen-Specific Immune Responses by Lipid-Based Delivery of mRNA Vaccines. Mol Ther, 21(1): 251–259.

Corbett KS, Flynn B, Foulds KE, et al., 2020, Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med, 383(16): 1544–1555.

Espeseth AS, Cejas PJ, Citron MP, et al., 2020, Modified mRNA/Lipid Nanoparticle-Based Vaccines Expressing Respiratory Syncytial Virus F Protein Variants are Immunogenic and Protective in Rodent Models of RSV Infection. NPJ Vaccines, 5(1): 16.

Liang F, Lindgren G, Lin A, et al., 2017, Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques. Molecular Therapy, 25(12): 2635–2647.

Lindgren G, Ols S, Liang F, et al., 2017, Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. Front Immunol, 8: 1539.

Singh A, 2021, Eliciting B Cell Immunity Against Infectious Diseases Using Nanovaccines. Nature Nanotechnology, 16(1): 16–24.

Lederer K, Castano D, Gomez Atria D, et al., 2020, SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity, 53(6): 1281–1295.

Pardi N, Hogan MJ, Naradikian MS, et al., 2018, Nucleoside-Modified mRNA Vaccines Induce Potent T Follicular Helper and Germinal Center B Cell Responses. J Exp Med, 215(6): 1571–1588.

Turner JS, O’halloran JA, Kalaidina E, et al., 2021, SARS-CoV-2 mRNA Vaccines Induce Persistent Human Germinal Centre Responses. Nature, 596(7870): 109–113.

Doria-Rose N, Suthar MS, Makowski M, et al., 2021, Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for COVID-19. N Engl J Med, 384(23): 2259–2261.

Yuan M, Huang D, Lee C-CD, et al., 2021, Structural and Functional Ramifications of Antigenic Drift in Recent SARS-CoV-2 Variants. Science, 373(6556): 818–823.

Wang Z, Schmidt F, Weisblum Y, et al., 2021, mRNA Vaccine-Elicited Antibodies to SARS-CoV-2 and Circulating Variants. Nature, 592(7855): 616–622.

Feldman RA, Fuhr R, Smolenov I, et al., 2019, mRNA Vaccines against H10N8 and H7N9 Influenza Viruses of Pandemic Potential are Immunogenic and Well Tolerated in Healthy Adults in Phase 1 Randomized Clinical Trials. Vaccine, 37(25): 3326–3334.

Shimabukuro TT, Cole M, Su JR, 2021, Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021. JAMA, 325(11): 1101–1102.

Besin G, Milton J, Sabnis S, et al., 2019, Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties. Immunohorizons, 3(7): 282–293.

Kozma GT, Shimizu T, Ishida T, et al., 2020, Anti-PEG Antibodies: Properties, Formation, Testing and Role in Adverse Immune Reactions to PEGylated Nano-Biopharmaceuticals. Adv Drug Deliv Rev, (154–155): 163–175.

Zhang N-N, Li X-F, Deng Y-Q, et al., 2020, A Thermostable mRNA Vaccine against COVID-19. Cell, 182(5): 1271–1283.

Qi Y, Fox CB, 2021, Development of Thermostable Vaccine Adjuvants. Expert Rev Vaccines, 20(5): 497–517.

Mestas J, Hughes CCW, 2004, Of Mice and Not Men: Differences Between Mouse and Human Immunology. J Immunol, 172(5): 2731–2738.

Brodin P, Davis MM, 2017, Human Immune System Variation. Nat Rev Immunol, 17(1): 21–29.

Renu S, Feliciano-Ruiz N, Lu F, et al., 2020, A Nanoparticle-Poly(I:C) Combination Adjuvant Enhances the Breadth of the Immune Response to Inactivated Influenza Virus Vaccine in Pigs. Vaccines (Basel), 8(2): 229.

Fujimoto Y, Hatoya S, Sugiura K, et al., 2024, Toll-Like Receptor 3-Stimulation and Aggregate-Formation Synergistically Enhances Anti-Inflammatory Activity of Feline Mesenchymal Stem Cells. J Vet Sci, 25(6): e86.

Ohta H, Ezoe S, Yamazaki K, et al., 2009, Application of Aluminum Hydroxide for an In Ovo Live Newcastle Disease Vaccine. Avian Dis, 53(3): 392–395.

De Gregorio E, Tritto E, Rappuoli R, 2008, Alum Adjuvanticity: Unraveling a Century Old Mystery. Eur J Immunol, 38(8): 2068–2071.

Wang T, Ma X, Lei Y, et al., 2016, Solid Lipid Nanoparticles Coated with Cross-Linked Polymeric Double Layer for Oral Delivery of Curcumin. Colloids Surf B Biointerfaces, 148: 1–11.

Wang T, Xue J, Hu Q, et al., 2017, Preparation of Lipid Nanoparticles with High Loading Capacity and Exceptional Gastrointestinal Stability for Potential oral Delivery Applications. J Colloid Interface Sci, 507: 119–130.

D’Souza AA, Shegokar R, 2016, Polyethylene Glycol (PEG): A Versatile Polymer for Pharmaceutical Applications. Expert Opin Drug Deliv, 13(9): 1257–1275.